{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,29]],"date-time":"2026-08-29T15:16:55Z","timestamp":1788016615847,"version":"build-2784847793"},"reference-count":95,"publisher":"Springer Science and Business Media LLC","license":[{"start":{"date-parts":[[2026,8,29]],"date-time":"2026-08-29T00:00:00Z","timestamp":1787961600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,8,29]],"date-time":"2026-08-29T00:00:00Z","timestamp":1787961600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Cancer Surviv"],"DOI":"10.1007\/s11764-026-02111-4","type":"journal-article","created":{"date-parts":[[2026,8,29]],"date-time":"2026-08-29T14:39:57Z","timestamp":1788014397000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Fertility in breast cancer survivorship: a scoping review"],"prefix":"10.1007","author":[{"given":"Sanjna","family":"Rajput","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elizabeth J.","family":"Cathcart-Rake","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kathryn J.","family":"Ruddy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chandra C. Paff","family":"Shenoy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christine","family":"Connors","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1861-3553","authenticated-orcid":false,"given":"Dame","family":"Idossa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,8,29]]},"reference":[{"key":"2111_CR1","unstructured":"National Cancer Institute. SEER Cancer Stat Facts: Female Breast Cancer. https:\/\/seer.cancer.gov\/statfacts\/html\/breast.html. Accessed 14 Nov 2025."},{"issue":"1","key":"2111_CR2","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2023.53331","volume":"7","author":"S Xu","year":"2024","unstructured":"Xu S, Murtagh S, Han Y, Wan F, Toriola AT. Breast cancer incidence among US women aged 20 to 49 years by race, stage, and hormone receptor status. JAMA Netw Open. 2024;7(1):e2353331. https:\/\/doi.org\/10.1001\/jamanetworkopen.2023.53331.","journal-title":"JAMA Netw Open"},{"issue":"20","key":"2111_CR3","doi-asserted-by":"publisher","first-page":"2333","DOI":"10.2217\/fon-2016-0176","volume":"12","author":"G Bedoschi","year":"2016","unstructured":"Bedoschi G, Navarro PA, Oktay K. Chemotherapy-induced damage to ovary: mechanisms and clinical impact. Future Oncol. 2016;12(20):2333\u201344. https:\/\/doi.org\/10.2217\/fon-2016-0176.","journal-title":"Future Oncol"},{"issue":"2","key":"2111_CR4","doi-asserted-by":"publisher","first-page":"638","DOI":"10.1016\/j.fertnstert.2009.03.045","volume":"94","author":"AH Partridge","year":"2010","unstructured":"Partridge AH, Ruddy KJ, Gelber S, Schapira L, Abusief M, Meyer M, et al. Ovarian reserve in women who remain premenopausal after chemotherapy for early stage breast cancer. Fertil Steril. 2010;94(2):638\u201344. https:\/\/doi.org\/10.1016\/j.fertnstert.2009.03.045.","journal-title":"Fertil Steril"},{"issue":"11","key":"2111_CR5","doi-asserted-by":"publisher","first-page":"1151","DOI":"10.1200\/JCO.2013.52.8877","volume":"32","author":"KJ Ruddy","year":"2014","unstructured":"Ruddy KJ, Gelber SI, Tamimi RM, Ginsburg ES, Schapira L, Come SE, et al. Prospective study of fertility concerns and preservation strategies in young women with breast cancer. J Clin Oncol. 2014;32(11):1151\u20136. https:\/\/doi.org\/10.1200\/JCO.2013.52.8877.","journal-title":"J Clin Oncol"},{"issue":"10","key":"2111_CR6","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/djv202","volume":"107","author":"NC Llarena","year":"2015","unstructured":"Llarena NC, Estevez SL, Tucker SL, Jeruss JS. Impact of fertility concerns on tamoxifen initiation and persistence. J Natl Cancer Inst. 2015;107(10):djv202. https:\/\/doi.org\/10.1093\/jnci\/djv202.","journal-title":"J Natl Cancer Inst"},{"issue":"1","key":"2111_CR7","doi-asserted-by":"publisher","first-page":"43","DOI":"10.3322\/caac.21319","volume":"66","author":"CD Runowicz","year":"2016","unstructured":"Runowicz CD, Leach CR, Henry NL, Henry KS, Mackey HT, Cowens-Alvarado RL, et al. American Cancer Society\/American Society of Clinical Oncology breast cancer survivorship care guideline. CA Cancer J Clin. 2016;66(1):43\u201373. https:\/\/doi.org\/10.3322\/caac.21319.","journal-title":"CA Cancer J Clin"},{"issue":"12","key":"2111_CR8","doi-asserted-by":"publisher","first-page":"1488","DOI":"10.1200\/JCO-24-02782","volume":"43","author":"HI Su","year":"2025","unstructured":"Su HI, Lacchetti C, Letourneau J, Partridge AH, Qamar R, Quinn GP, et al. Fertility preservation in people with cancer: ASCO guideline update. J Clin Oncol. 2025;43(12):1488\u2013515. https:\/\/doi.org\/10.1200\/JCO-24-02782.","journal-title":"J Clin Oncol"},{"key":"2111_CR9","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2021.690320","volume":"11","author":"E Blondeaux","year":"2021","unstructured":"Blondeaux E, Massarotti C, Fontana V, Poggio F, Arecco L, Fregatti P, et al. The PREgnancy and FERtility (PREFER) study investigating the need for ovarian function and\/or fertility preservation strategies in premenopausal women with early breast cancer. Front Oncol. 2021;11:690320. https:\/\/doi.org\/10.3389\/fonc.2021.690320.","journal-title":"Front Oncol"},{"key":"2111_CR10","doi-asserted-by":"publisher","first-page":"e12520","DOI":"10.1200\/JCO.2022.40.16_suppl.e12520","volume":"40","author":"D Isseroff","year":"2022","unstructured":"Isseroff D, Thorn B, Chang C, Abdo N, Semler R, Gemignani M, et al. Fertility preservation decisions and outcomes of young women with breast cancer. J Clin Oncol. 2022;40:e12520\u2013e12520. https:\/\/doi.org\/10.1200\/JCO.2022.40.16_suppl.e12520.","journal-title":"J Clin Oncol"},{"key":"2111_CR11","doi-asserted-by":"publisher","DOI":"10.1007\/s11764-025-01850-0","author":"J Stal","year":"2025","unstructured":"Stal J, Yi SY, Roche CI, Freyer DR, Kim SE, Milam JE, et al. Are guidelines guiding? A mixed methods study examining the integration of ASCO fertility discussion guidelines in practice among oncologists and adolescents and young adults at an NCI-designated Comprehensive Cancer Center. J Cancer Surviv. 2025. https:\/\/doi.org\/10.1007\/s11764-025-01850-0.","journal-title":"J Cancer Surviv"},{"issue":"18","key":"2111_CR12","doi-asserted-by":"publisher","first-page":"4579","DOI":"10.1002\/cncr.26649","volume":"118","author":"JM Letourneau","year":"2012","unstructured":"Letourneau JM, Smith JF, Ebbel EE, Craig A, Katz PP, Cedars MI, et al. Racial, socioeconomic, and demographic disparities in access to fertility preservation in young women diagnosed with cancer. Cancer. 2012;118(18):4579\u201388. https:\/\/doi.org\/10.1002\/cncr.26649.","journal-title":"Cancer"},{"issue":"11","key":"2111_CR13","doi-asserted-by":"publisher","first-page":"1209","DOI":"10.18632\/oncotarget.26632","volume":"10","author":"P Ntellas","year":"2019","unstructured":"Ntellas P, Spathas N, Agelaki S, Zintzaras E, Saloustros E. Taxane & cyclophosphamide vs anthracycline & taxane-based chemotherapy as adjuvant treatment for breast cancer: a pooled analysis of randomized controlled trials by the Hellenic Academy of Oncology. Oncotarget. 2019;10(11):1209\u201316. https:\/\/doi.org\/10.18632\/oncotarget.26632.","journal-title":"Oncotarget"},{"issue":"1","key":"2111_CR14","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1007\/s43032-023-01294-w","volume":"31","author":"Q Xie","year":"2024","unstructured":"Xie Q, Liao Q, Wang L, Zhang Y, Chen J, Bai H, et al. The dominant mechanism of cyclophosphamide-induced damage to ovarian reserve: premature activation or apoptosis of primordial follicles? Reprod Sci. 2024;31(1):30\u201344. https:\/\/doi.org\/10.1007\/s43032-023-01294-w.","journal-title":"Reprod Sci"},{"issue":"12","key":"2111_CR15","doi-asserted-by":"publisher","first-page":"1243","DOI":"10.1055\/s-0035-1558184","volume":"75","author":"S Findeklee","year":"2015","unstructured":"Findeklee S, Lotz L, Heusinger K, Hoffmann I, Dittrich R, Beckmann MW. Fertility protection in female oncology patients: how should patients be counseled? Geburtshilfe Frauenheilkd. 2015;75(12):1243\u20139. https:\/\/doi.org\/10.1055\/s-0035-1558184.","journal-title":"Geburtshilfe Frauenheilkd"},{"issue":"8","key":"2111_CR16","doi-asserted-by":"publisher","first-page":"553","DOI":"10.1093\/molehr\/gaaa043","volume":"26","author":"KJ Szymanska","year":"2020","unstructured":"Szymanska KJ, Tan X, Oktay K. Unraveling the mechanisms of chemotherapy-induced damage to human primordial follicle reserve: road to developing therapeutics for fertility preservation and reversing ovarian aging. Mol Hum Reprod. 2020;26(8):553\u201366. https:\/\/doi.org\/10.1093\/molehr\/gaaa043.","journal-title":"Mol Hum Reprod"},{"key":"2111_CR17","doi-asserted-by":"publisher","unstructured":"Weidlinger S, Weidlinger M, Schramm RM, Vidal A, Pape J, Karrer T, Rabaglio M, von Wolff M. High impact of chemotherapy on ovarian reserve in breast cancer survivors of reproductive age: a systematic review and meta-analysis. Breast. 2025;82:104514. https:\/\/doi.org\/10.1016\/j.breast.2025.104514.","DOI":"10.1016\/j.breast.2025.104514"},{"issue":"4","key":"2111_CR18","doi-asserted-by":"publisher","DOI":"10.1093\/hropen\/hoaa052","volume":"2020","author":"RA Anderson","year":"2020","unstructured":"ESHRE Guideline Group on Female Fertility Preservation, Anderson RA, Amant F, Braat D, D\u2019Angelo A, Chuva de Sousa Lopes SM, et al. ESHRE guideline: female fertility preservation. Hum Reprod Open. 2020;2020(4):hoaa052. https:\/\/doi.org\/10.1093\/hropen\/hoaa052.","journal-title":"Hum Reprod Open"},{"issue":"3","key":"2111_CR19","doi-asserted-by":"publisher","first-page":"241","DOI":"10.1016\/j.clbc.2023.01.006","volume":"23","author":"MG Razeti","year":"2023","unstructured":"Razeti MG, Soldato D, Arecco L, Levaggi A, Puglisi S, Solinas C, Agostinetto E, Spinaci S, Lapuchesky L, Genova C, Massarotti C, Lambertini M. Approaches to fertility preservation for young women with breast cancer. Clin Breast Cancer. 2023;23(3):241\u20138. https:\/\/doi.org\/10.1016\/j.clbc.2023.01.006.","journal-title":"Clin Breast Cancer"},{"issue":"12","key":"2111_CR20","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2022.859974","volume":"5","author":"Y Wang","year":"2022","unstructured":"Wang Y, Li Y, Liang J, Zhang N, Yang Q. Chemotherapy-induced amenorrhea and its prognostic significance in premenopausal women with breast cancer: an updated meta-analysis. Front Oncol. 2022;5(12): 859974. https:\/\/doi.org\/10.3389\/fonc.2022.859974.","journal-title":"Front Oncol"},{"issue":"1","key":"2111_CR21","doi-asserted-by":"publisher","first-page":"102","DOI":"10.1186\/s13048-019-0581-6","volume":"12","author":"C Silva","year":"2019","unstructured":"Silva C, Ribeiro Rama AC, Reis Soares S, Moura-Ramos M, Almeida-Santos T. Adverse reproductive health outcomes in a cohort of young women with breast cancer exposed to systemic treatments. J Ovarian Res. 2019;12(1):102. https:\/\/doi.org\/10.1186\/s13048-019-0581-6.","journal-title":"J Ovarian Res"},{"issue":"3","key":"2111_CR22","doi-asserted-by":"publisher","first-page":"177","DOI":"10.5152\/ejbh.2020.5114","volume":"16","author":"F \u00c7elebi","year":"2020","unstructured":"\u00c7elebi F, Ordu \u00c7, Ilg\u00fcn S, Ozt\u00fcrk A, Erdo\u011fan Iyig\u00fcn Z, Al\u00e7o G, et al. The effect of systemic chemotherapy on ovarian function: a prospective clinical trial. Eur J Breast Health. 2020;16(3):177\u201382. https:\/\/doi.org\/10.5152\/ejbh.2020.5114.","journal-title":"Eur J Breast Health"},{"issue":"4","key":"2111_CR23","doi-asserted-by":"publisher","first-page":"615","DOI":"10.1007\/s00432-010-0894-8","volume":"137","author":"K Sakurai","year":"2011","unstructured":"Sakurai K, Enomoto K, Amano S. Recovery of menstruation after long-term chemotherapy and endocrine therapy in pre-menopausal patients with breast cancer. J Cancer Res Clin Oncol. 2011;137(4):615\u201320. https:\/\/doi.org\/10.1007\/s00432-010-0894-8.","journal-title":"J Cancer Res Clin Oncol"},{"issue":"1","key":"2111_CR24","doi-asserted-by":"publisher","first-page":"11","DOI":"10.5653\/cerm.2020.04049","volume":"48","author":"JH Lee","year":"2021","unstructured":"Lee JH, Choi YS. The role of gonadotropin-releasing hormone agonists in female fertility preservation. Clin Exp Reprod Med. 2021;48(1):11\u201326. https:\/\/doi.org\/10.5653\/cerm.2020.04049.","journal-title":"Clin Exp Reprod Med"},{"issue":"10","key":"2111_CR25","doi-asserted-by":"publisher","first-page":"1352","DOI":"10.1093\/jnci\/djab065","volume":"113","author":"KD Yu","year":"2021","unstructured":"Yu KD, Ge JY, Liu XY, Mo M, He M, Shao ZM. Cyclophosphamide-free adjuvant chemotherapy for ovarian protection in young women with breast cancer: a randomized phase 3 trial. J Natl Cancer Inst. 2021;113(10):1352\u20139. https:\/\/doi.org\/10.1093\/jnci\/djab065.","journal-title":"J Natl Cancer Inst"},{"issue":"11","key":"2111_CR26","doi-asserted-by":"publisher","first-page":"1547","DOI":"10.1634\/theoncologist.2011-0121","volume":"16","author":"G Braems","year":"2011","unstructured":"Braems G, Denys H, De Wever O, Cocquyt V, Van den Broecke R. Use of tamoxifen before and during pregnancy. Oncologist. 2011;16(11):1547\u201351. https:\/\/doi.org\/10.1634\/theoncologist.2011-0121.","journal-title":"Oncologist"},{"issue":"18","key":"2111_CR27","doi-asserted-by":"publisher","first-page":"1645","DOI":"10.1056\/NEJMoa2212856","volume":"388","author":"AH Partridge","year":"2023","unstructured":"Partridge AH, Niman SM, Ruggeri M, Peccatori FA, Azim HA Jr, Colleoni M, et al. Interrupting endocrine therapy to attempt pregnancy after breast cancer. N Engl J Med. 2023;388(18):1645\u201356. https:\/\/doi.org\/10.1056\/NEJMoa2212856.","journal-title":"N Engl J Med"},{"key":"2111_CR28","doi-asserted-by":"publisher","unstructured":"Pagani O, Niman SM, Ruggeri M, Peccatori FA, Azim HA Jr, Colleoni M, Saura C, Shimizu C, S\u00e6tersdal AB, Kroep JR,Warner E, Amant F, Mailliez A, Moore HCF, Ruiz-Borrego M, Walshe JM, Borges VF, Gombos A, Kataoka A, Rousset-Jablonski C, Borstnar S, Takei J, Lee JE, Saunders C, Bjelic-Radisic V, Susnjar S, Cardoso F, Klar NJ, Ferreiro T, Ribi K,Ruddy KJ, Kammler R, El-Abed S, Viale G, Piccart M, Korde LA, Goldhirsch A, Gelber RD, Partridge AH. International breast cancer study group and the positive trial consortium. Updated results of the positive (pregnancy outcome and safety of interrupting therapy for women with endocrine responsive breast cancer) trial. Ann Oncol. 2026;37(9):1230\u201341. https:\/\/doi.org\/10.1016\/j.annonc.2026.05.699.","DOI":"10.1016\/j.annonc.2026.05.699"},{"key":"2111_CR29","doi-asserted-by":"publisher","unstructured":"Schmid P, Cortes J, Pusztai L, McArthur H, K\u00fcmmel S, Bergh J, Denkert C, Park YH, Hui R, Harbeck N, Takahashi M, Foukakis T, Fasching PA, Cardoso F, Untch M, Jia L, Karantza V, Zhao J, Aktan G, Dent R, O'Shaughnessy J; Keynote-522 Investigators. Pembrolizumab for early triple-negative breast cancer. N Engl J Med. 2020;382(9):810\u201321. https:\/\/doi.org\/10.1056\/NEJMoa1910549.","DOI":"10.1056\/NEJMoa1910549"},{"key":"2111_CR30","doi-asserted-by":"publisher","first-page":"12013","DOI":"10.1200\/JCO.2023.41.16_suppl.12013","volume":"41","author":"EI Buchbinder","year":"2023","unstructured":"Buchbinder EI, Song Z, Lee SJ, Keefe KW, Manos MP, Tarhini AA, et al. Impact of immune checkpoint inhibition on ovarian reserve in patients with melanoma enrolled in the ECOG-ACRIN E1609 adjuvant trial. J Clin Oncol. 2023;41:12013.","journal-title":"J Clin Oncol"},{"issue":"4","key":"2111_CR31","doi-asserted-by":"publisher","first-page":"312","DOI":"10.4103\/tcmj.tcmj_255_19","volume":"32","author":"A Koyyada","year":"2020","unstructured":"Koyyada A, Orsu P. Role of hypothyroidism and associated pathways in pregnancy and infertility: clinical insights. Tzu Chi Med J. 2020;32(4):312\u20137. https:\/\/doi.org\/10.4103\/tcmj.tcmj_255_19.","journal-title":"Tzu Chi Med J"},{"issue":"8","key":"2111_CR32","doi-asserted-by":"publisher","first-page":"1452","DOI":"10.1093\/humrep\/deaf096","volume":"40","author":"L Arecco","year":"2025","unstructured":"Arecco L, de Moura LL, Gentile G, Jankovic K, Stana M, Ottonello S, et al. Gonadotoxicity of immunotherapy and targeted agents in patients with cancer and impact on subsequent pregnancies. Hum Reprod. 2025;40(8):1452\u201366. https:\/\/doi.org\/10.1093\/humrep\/deaf096.","journal-title":"Hum Reprod"},{"issue":"1","key":"2111_CR33","doi-asserted-by":"publisher","first-page":"86","DOI":"10.1093\/jnci\/djy094","volume":"111","author":"M Lambertini","year":"2019","unstructured":"Lambertini M, Campbell C, Bines J, Korde LA, Izquierdo M, Fumagalli D, et al. Adjuvant anti-HER2 therapy, treatment-related amenorrhea, and survival in premenopausal HER2-positive early breast cancer patients. J Natl Cancer Inst. 2019;111(1):86\u201394. https:\/\/doi.org\/10.1093\/jnci\/djy094.","journal-title":"J Natl Cancer Inst"},{"issue":"3","key":"2111_CR34","doi-asserted-by":"publisher","first-page":"589","DOI":"10.1007\/s10549-015-3426-z","volume":"151","author":"KJ Ruddy","year":"2015","unstructured":"Ruddy KJ, Guo H, Barry W, Dang CT, Yardley DA, Moy B, et al. Chemotherapy-related amenorrhea after adjuvant paclitaxel-trastuzumab (APT trial). Breast Cancer Res Treat. 2015;151(3):589\u201396. https:\/\/doi.org\/10.1007\/s10549-015-3426-z.","journal-title":"Breast Cancer Res Treat"},{"issue":"12","key":"2111_CR35","doi-asserted-by":"publisher","DOI":"10.3390\/biomedicines8120577","volume":"8","author":"M Levi","year":"2020","unstructured":"Levi M, Goshen-Lago T, Yerushalmi R, Granot T, Stemmer SM, Shalgi R, et al. Anti-HER2\/neu antibody reduces chemotherapy-induced ovarian toxicity-from bench to bedside. Biomedicines. 2020;8(12):577. https:\/\/doi.org\/10.3390\/biomedicines8120577.","journal-title":"Biomedicines"},{"issue":"1","key":"2111_CR36","doi-asserted-by":"publisher","first-page":"33","DOI":"10.6004\/jnccn.2022.7065","volume":"21","author":"M Lambertini","year":"2023","unstructured":"Lambertini M, Ceppi M, Anderson RA, Cameron DA, Bruzzone M, Franzoi MA, et al. Impact of anti-HER2 therapy alone and with weekly paclitaxel on the ovarian reserve of young women with HER2-positive breast cancer. J Natl Compr Canc Netw. 2023;21(1):33-41.e16. https:\/\/doi.org\/10.6004\/jnccn.2022.7065.","journal-title":"J Natl Compr Canc Netw"},{"issue":"1","key":"2111_CR37","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1007\/s10549-021-06267-8","volume":"189","author":"KJ Ruddy","year":"2021","unstructured":"Ruddy KJ, Zheng Y, Tayob N, Hu J, Dang CT, Yardley DA, et al. Chemotherapy-related amenorrhea (CRA) after adjuvant ado-trastuzumab emtansine (T-DM1) compared to paclitaxel in combination with trastuzumab (TH) (TBCRC033: ATEMPT trial). Breast Cancer Res Treat. 2021;189(1):103\u201310. https:\/\/doi.org\/10.1007\/s10549-021-06267-8.","journal-title":"Breast Cancer Res Treat"},{"issue":"20","key":"2111_CR38","doi-asserted-by":"publisher","first-page":"4923","DOI":"10.3390\/cancers15204923","volume":"15","author":"G Scavone","year":"2023","unstructured":"Scavone G, Ottonello S, Blondeaux E, Arecco L, Scaruffi P, Stigliani S, et al. The role of cyclin-dependent kinases (CDK) 4\/6 in the ovarian tissue and the possible effects of their exogenous inhibition. Cancers (Basel). 2023;15(20):4923. https:\/\/doi.org\/10.3390\/cancers15204923.","journal-title":"Cancers (Basel)"},{"issue":"6","key":"2111_CR39","doi-asserted-by":"publisher","DOI":"10.1016\/j.esmoop.2024.103466","volume":"9","author":"F Marm\u00e9","year":"2024","unstructured":"Marm\u00e9 F, Martin M, Untch M, Thode C, Bonnefoi H, Kim SB, et al. Palbociclib combined with endocrine treatment in hormone receptor-positive, HER2-negative breast cancer patients with high relapse risk after neoadjuvant chemotherapy: subgroup analyses of premenopausal patients in PENELOPE-B. ESMO Open. 2024;9(6):103466. https:\/\/doi.org\/10.1016\/j.esmoop.2024.103466.","journal-title":"ESMO Open"},{"key":"2111_CR40","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2024.114010","volume":"202","author":"H Helgadottir","year":"2024","unstructured":"Helgadottir H, Matikas A, Fernebro J, Fr\u00f6din JE, Ekman S, Rodriguez-Wallberg KA. Fertility and reproductive concerns related to the new generation of cancer drugs and the clinical implication for young individuals undergoing treatments for solid tumors. Eur J Cancer. 2024;202:114010. https:\/\/doi.org\/10.1016\/j.ejca.2024.114010.","journal-title":"Eur J Cancer"},{"key":"2111_CR41","doi-asserted-by":"publisher","first-page":"375","DOI":"10.1007\/s12609-020-00394-9","volume":"12","author":"S Beyer","year":"2020","unstructured":"Beyer S, Sandu A, White J. Impact and timing of breast cancer radiation therapy and fertility preservation. Curr Breast Cancer Rep. 2020;12:375\u201380. https:\/\/doi.org\/10.1007\/s12609-020-00394-9.","journal-title":"Curr Breast Cancer Rep"},{"issue":"11","key":"2111_CR42","doi-asserted-by":"publisher","first-page":"711","DOI":"10.1097\/OGX.0000000000001441","volume":"80","author":"M Blasingame","year":"2025","unstructured":"Blasingame M, Kuller JA, Dotters-Katz SK, Trotter K, Kerner N. Contraceptive use in breast cancer patients and survivors. Obstet Gynecol Surv. 2025;80(11):711\u20136. https:\/\/doi.org\/10.1097\/OGX.0000000000001441.","journal-title":"Obstet Gynecol Surv"},{"issue":"17","key":"2111_CR43","doi-asserted-by":"publisher","first-page":"1657","DOI":"10.1056\/NEJMra1614676","volume":"377","author":"J Donnez","year":"2017","unstructured":"Donnez J, Dolmans MM. Fertility preservation in women. N Engl J Med. 2017;377(17):1657\u201365. https:\/\/doi.org\/10.1056\/NEJMra1614676.","journal-title":"N Engl J Med"},{"key":"2111_CR44","doi-asserted-by":"publisher","unstructured":"Practice Committee of the American Society for Reproductive Medicine. Fertility preservation in patients undergoing gonadotoxic therapy or gonadectomy: a committee opinion. Fertil Steril. 2019;112(6):1022\u201333.\u00a0https:\/\/doi.org\/10.1016\/j.fertnstert.2019.09.013. ISSN 0015\u20130282.","DOI":"10.1016\/j.fertnstert.2019.09.013"},{"issue":"1","key":"2111_CR45","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1080\/23809000.2017.1270760","volume":"2","author":"M Lambertini","year":"2016","unstructured":"Lambertini M, Pescio MC, Viglietti G, Goldrat O, Del Mastro L, Anserini P, et al. Methods of controlled ovarian stimulation for embryo\/oocyte cryopreservation in breast cancer patients. Expert Rev Qual Life Cancer Care. 2016;2(1):47\u201359. https:\/\/doi.org\/10.1080\/23809000.2017.1270760.","journal-title":"Expert Rev Qual Life Cancer Care"},{"issue":"8","key":"2111_CR46","doi-asserted-by":"publisher","first-page":"1195","DOI":"10.1007\/s10815-015-0507-1","volume":"32","author":"L Rienzi","year":"2015","unstructured":"Rienzi L, Ubaldi FM. Oocyte versus embryo cryopreservation for fertility preservation in cancer patients: guaranteeing a women\u2019s autonomy. J Assist Reprod Genet. 2015;32(8):1195\u20136. https:\/\/doi.org\/10.1007\/s10815-015-0507-1.","journal-title":"J Assist Reprod Genet"},{"issue":"2","key":"2111_CR47","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1093\/humupd\/dmw038","volume":"23","author":"L Rienzi","year":"2017","unstructured":"Rienzi L, Gracia C, Maggiulli R, LaBarbera AR, Kaser DJ, Ubaldi FM, et al. Oocyte, embryo and blastocyst cryopreservation in ART: systematic review and meta-analysis comparing slow-freezing versus vitrification to produce evidence for the development of global guidance. Hum Reprod Update. 2017;23(2):139\u201355. https:\/\/doi.org\/10.1093\/humupd\/dmw038.","journal-title":"Hum Reprod Update"},{"issue":"4","key":"2111_CR48","doi-asserted-by":"publisher","first-page":"929","DOI":"10.1093\/humrep\/deaa029","volume":"35","author":"A Marklund","year":"2020","unstructured":"Marklund A, Eloranta S, Wikander I, Kitlinski ML, Lood M, Nedstrand E, et al. Efficacy and safety of controlled ovarian stimulation using GnRH antagonist protocols for emergency fertility preservation in young women with breast cancer-a prospective nationwide Swedish multicenter study. Hum Reprod. 2020;35(4):929\u201338. https:\/\/doi.org\/10.1093\/humrep\/deaa029.","journal-title":"Hum Reprod"},{"issue":"19","key":"2111_CR49","doi-asserted-by":"publisher","first-page":"1994","DOI":"10.1200\/JCO.2018.78.1914","volume":"36","author":"K Oktay","year":"2018","unstructured":"Oktay K, Harvey BE, Partridge AH, Quinn GP, Reinecke J, Taylor HS, et al. Fertility preservation in patients with cancer: ASCO clinical practice guideline update. J Clin Oncol. 2018;36(19):1994\u20132001. https:\/\/doi.org\/10.1200\/JCO.2018.78.1914.","journal-title":"J Clin Oncol"},{"issue":"5","key":"2111_CR50","doi-asserted-by":"publisher","first-page":"1033","DOI":"10.1093\/humrep\/dex027","volume":"32","author":"RJ Rodgers","year":"2017","unstructured":"Rodgers RJ, Reid GD, Koch J, Deans R, Ledger WL, Friedlander M, et al. The safety and efficacy of controlled ovarian hyperstimulation for fertility preservation in women with early breast cancer: a systematic review. Hum Reprod. 2017;32(5):1033\u201345. https:\/\/doi.org\/10.1093\/humrep\/dex027.","journal-title":"Hum Reprod"},{"issue":"22","key":"2111_CR51","doi-asserted-by":"publisher","first-page":"2424","DOI":"10.1200\/JCO.2014.59.3723","volume":"33","author":"K Oktay","year":"2015","unstructured":"Oktay K, Turan V, Bedoschi G, Pacheco FS, Moy F. Fertility preservation success subsequent to concurrent aromatase inhibitor treatment and ovarian stimulation in women with breast cancer. J Clin Oncol. 2015;33(22):2424\u20139. https:\/\/doi.org\/10.1200\/JCO.2014.59.3723.","journal-title":"J Clin Oncol"},{"issue":"2","key":"2111_CR52","doi-asserted-by":"publisher","first-page":"262","DOI":"10.1016\/j.fertnstert.2023.12.001","volume":"121","author":"PC Brady","year":"2024","unstructured":"Brady PC. Ovarian tissue transplantation: a science coming of age. Fertil Steril. 2024;121(2):262\u20133. https:\/\/doi.org\/10.1016\/j.fertnstert.2023.12.001.","journal-title":"Fertil Steril"},{"issue":"3","key":"2111_CR53","doi-asserted-by":"publisher","first-page":"400","DOI":"10.1093\/humupd\/dmac003","volume":"28","author":"H Khattak","year":"2022","unstructured":"Khattak H, Malhas R, Craciunas L, Afifi Y, Amorim CA, Fishel S, et al. Fresh and cryopreserved ovarian tissue transplantation for preserving reproductive and endocrine function: a systematic review and individual patient data meta-analysis. Hum Reprod Update. 2022;28(3):400\u201316. https:\/\/doi.org\/10.1093\/humupd\/dmac003.","journal-title":"Hum Reprod Update"},{"issue":"8","key":"2111_CR54","doi-asserted-by":"publisher","first-page":"1167","DOI":"10.1007\/s10815-015-0544-9","volume":"32","author":"J Donnez","year":"2015","unstructured":"Donnez J, Dolmans MM. Ovarian cortex transplantation: 60 reported live births brings the success and worldwide expansion of the technique towards routine clinical practice. J Assist Reprod Genet. 2015;32(8):1167\u201370. https:\/\/doi.org\/10.1007\/s10815-015-0544-9.","journal-title":"J Assist Reprod Genet"},{"issue":"9","key":"2111_CR55","doi-asserted-by":"publisher","first-page":"2031","DOI":"10.1093\/humrep\/dew165","volume":"31","author":"H Van der Ven","year":"2016","unstructured":"Van der Ven H, Liebenthron J, Beckmann M, Toth B, Korell M, Kr\u00fcssel J, et al. Ninety-five orthotopic transplantations in 74 women of ovarian tissue after cytotoxic treatment in a fertility preservation network: tissue activity, pregnancy and delivery rates. Hum Reprod. 2016;31(9):2031\u201341. https:\/\/doi.org\/10.1093\/humrep\/dew165.","journal-title":"Hum Reprod"},{"key":"2111_CR56","doi-asserted-by":"publisher","unstructured":"Bastings L, Beerendonk CC, Westphal JR, Massuger LF, Kaal SE, van Leeuwen FE, Braat DD, Peek R. Autotransplantation of cryopreserved ovarian tissue in cancer survivors and the risk of reintroducing malignancy: a systematic review. Hum Reprod Update. 2013;19(5):483\u2013506. https:\/\/doi.org\/10.1093\/humupd\/dmt020.","DOI":"10.1093\/humupd\/dmt020"},{"issue":"19","key":"2111_CR57","doi-asserted-by":"publisher","first-page":"1981","DOI":"10.1200\/JCO.2018.78.0858","volume":"36","author":"M Lambertini","year":"2018","unstructured":"Lambertini M, Moore HCF, Leonard RCF, Loibl S, Munster P, Bruzzone M, et al. Gonadotropin-releasing hormone agonists during chemotherapy for preservation of ovarian function and fertility in premenopausal patients with early breast cancer: a systematic review and meta-analysis of individual patient-level data. J Clin Oncol. 2018;36(19):1981\u201390. https:\/\/doi.org\/10.1200\/JCO.2018.78.0858.","journal-title":"J Clin Oncol"},{"issue":"10","key":"2111_CR58","doi-asserted-by":"publisher","first-page":"923","DOI":"10.1056\/NEJMoa1413204","volume":"372","author":"HC Moore","year":"2015","unstructured":"Moore HC, Unger JM, Phillips KA, Boyle F, Hitre E, Porter D, et al. Goserelin for ovarian protection during breast-cancer adjuvant chemotherapy. N Engl J Med. 2015;372(10):923\u201332. https:\/\/doi.org\/10.1056\/NEJMoa1413204.","journal-title":"N Engl J Med"},{"issue":"13","key":"2111_CR59","doi-asserted-by":"publisher","first-page":"117955811982839","DOI":"10.1177\/1179558119828393","volume":"9","author":"M Lambertini","year":"2019","unstructured":"Lambertini M, Richard F, Nguyen B, Viglietti G, Villarreal-Garza C. Ovarian function and fertility preservation in breast cancer: should gonadotropin-releasing hormone agonist be administered to all premenopausal patients receiving chemotherapy? Clin Med Insights Reprod Health. 2019;9(13):1179558119828393. https:\/\/doi.org\/10.1177\/1179558119828393.","journal-title":"Clin Med Insights Reprod Health"},{"issue":"6","key":"2111_CR60","doi-asserted-by":"publisher","first-page":"1055","DOI":"10.1093\/humrep\/dez060","volume":"34","author":"VNA Ho","year":"2019","unstructured":"Ho VNA, Braam SC, Pham TD, Mol BW, Vuong LN. The effectiveness and safety of in vitro maturation of oocytes versus in vitro fertilization in women with a high antral follicle count. Hum Reprod. 2019;34(6):1055\u201364. https:\/\/doi.org\/10.1093\/humrep\/dez060.","journal-title":"Hum Reprod"},{"issue":"3","key":"2111_CR61","doi-asserted-by":"publisher","first-page":"477","DOI":"10.26574\/maedica.2023.18.3.477","volume":"18","author":"VN Varlas","year":"2023","unstructured":"Varlas VN, Bors RG, Cretoiu R, Carp-Veliscu A, Mehedintu C, Cirstoiu M. The artificial ovary: the next step in fertility preservation in cancer patients. Maedica (Bucur). 2023;18(3):477\u201382. https:\/\/doi.org\/10.26574\/maedica.2023.18.3.477.","journal-title":"Maedica (Bucur)"},{"issue":"4","key":"2111_CR62","doi-asserted-by":"publisher","first-page":"585","DOI":"10.1016\/j.fertnstert.2025.08.017","volume":"124","author":"S Kalluru","year":"2025","unstructured":"Kalluru S, Vu M, Brady PC. Fertility preservation for cancer: referral guidelines, treatment options, and specific considerations. Fertil Steril. 2025;124(4):585\u201392. https:\/\/doi.org\/10.1016\/j.fertnstert.2025.08.017.","journal-title":"Fertil Steril"},{"issue":"22","key":"2111_CR63","doi-asserted-by":"publisher","first-page":"3938","DOI":"10.1002\/cncr.29637","volume":"121","author":"NA Deshpande","year":"2015","unstructured":"Deshpande NA, Braun IM, Meyer FL. Impact of fertility preservation counseling and treatment on psychological outcomes among women with cancer: a systematic review. Cancer. 2015;121(22):3938\u201347. https:\/\/doi.org\/10.1002\/cncr.29637.","journal-title":"Cancer"},{"issue":"6","key":"2111_CR64","doi-asserted-by":"publisher","first-page":"1710","DOI":"10.1002\/cncr.26459","volume":"118","author":"JM Letourneau","year":"2012","unstructured":"Letourneau JM, Ebbel EE, Katz PP, Katz A, Ai WZ, Chien AJ, et al. Pretreatment fertility counseling and fertility preservation improve quality of life in reproductive age women with cancer. Cancer. 2012;118(6):1710\u20137. https:\/\/doi.org\/10.1002\/cncr.26459.","journal-title":"Cancer"},{"issue":"5","key":"2111_CR65","doi-asserted-by":"publisher","first-page":"1113","DOI":"10.1016\/j.fertnstert.2016.01.017","volume":"105","author":"EY Adashi","year":"2016","unstructured":"Adashi EY, Dean LA. Access to and use of infertility services in the United States: framing the challenges. Fertil Steril. 2016;105(5):1113\u20138. https:\/\/doi.org\/10.1016\/j.fertnstert.2016.01.017.","journal-title":"Fertil Steril"},{"issue":"4","key":"2111_CR66","doi-asserted-by":"publisher","first-page":"848","DOI":"10.1097\/AOG.0000000000003758","volume":"135","author":"MR Sax","year":"2020","unstructured":"Sax MR, Pavlovic Z, DeCherney AH. Inconsistent mandated access to fertility preservation: a review of relevant state legislation. Obstet Gynecol. 2020;135(4):848\u201351. https:\/\/doi.org\/10.1097\/AOG.0000000000003758.","journal-title":"Obstet Gynecol"},{"issue":"10","key":"2111_CR67","doi-asserted-by":"publisher","first-page":"1364","DOI":"10.1001\/jamaoncol.2023.2780","volume":"9","author":"BJ Peipert","year":"2023","unstructured":"Peipert BJ, Potapragada NR, Lantos PM, Harris BS, Reinecke J, Goldman KN. A geospatial analysis of disparities in access to oncofertility services. JAMA Oncol. 2023;9(10):1364\u201370. https:\/\/doi.org\/10.1001\/jamaoncol.2023.2780.","journal-title":"JAMA Oncol"},{"key":"2111_CR68","unstructured":"Oncofertility coverage mandates expand to 21 states and DC as political momentum builds Gaps persist as patients face harrowing decisions and huge copays - The Cancer Letter. Cancer Lett. 2025. https:\/\/cancerletter.com\/clinical\/20251121_1\/\u200c.\u00a0Accessed 26 Nov 2025."},{"issue":"5","key":"2111_CR69","doi-asserted-by":"publisher","first-page":"1435","DOI":"10.1007\/s11764-022-01187-y","volume":"17","author":"C Meernik","year":"2023","unstructured":"Meernik C, Engel SM, Wardell A, Baggett CD, Gupta P, Rodriguez-Ormaza N, et al. Disparities in fertility preservation use among adolescent and young adult women with cancer. J Cancer Surviv. 2023;17(5):1435\u201344. https:\/\/doi.org\/10.1007\/s11764-022-01187-y.","journal-title":"J Cancer Surviv"},{"issue":"6","key":"2111_CR70","doi-asserted-by":"publisher","first-page":"906","DOI":"10.1007\/s11764-020-00983-8","volume":"15","author":"AN Vest","year":"2021","unstructured":"Vest AN, Kuete NT, Mehta A. Is fertility preservation a part of comprehensive cancer care in the USA? A study of NCI-designated cancer center websites. J Cancer Surviv. 2021;15(6):906\u201311. https:\/\/doi.org\/10.1007\/s11764-020-00983-8.","journal-title":"J Cancer Surviv"},{"issue":"1","key":"2111_CR71","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-023-30423-3","volume":"13","author":"F Martinet-Kosinski","year":"2023","unstructured":"Martinet-Kosinski F, Lamy S, Bauvin E, Dalenc F, Vaysse C, Grosclaude P. Access to information and oncofertility consultation for young women with breast cancer: a population-based study. Sci Rep. 2023;13(1):3313. https:\/\/doi.org\/10.1038\/s41598-023-30423-3.","journal-title":"Sci Rep"},{"key":"2111_CR72","doi-asserted-by":"publisher","unstructured":"Yuen S, McCool K, Bharucha M, Narloch K, Zhu J, Yong H. Evaluating trends in fertility counseling among reproductive-age patients with breast cancer. Ann Surg Oncol. 2025;32(11):8425\u201331. https:\/\/doi.org\/10.1245\/s10434-025-17857-x.","DOI":"10.1245\/s10434-025-17857-x"},{"key":"2111_CR73","doi-asserted-by":"publisher","unstructured":"Ethics Committee of the American Society for Reproductive Medicine. Fertility preservation and reproduction in patients facing gonadotoxic therapies: an Ethics Committee opinion. Fertil Steril. 2018;110(3):380\u20136. https:\/\/doi.org\/10.1016\/j.fertnstert.2018.05.034.","DOI":"10.1016\/j.fertnstert.2018.05.034"},{"key":"2111_CR74","doi-asserted-by":"publisher","unstructured":"Ethics Committee of the American Society for Reproductive Medicine. Posthumous retrieval and use of gametes or embryos: an Ethics Committee opinion. Fertil Steril. 2018;110(1):45\u20139. https:\/\/doi.org\/10.1016\/j.fertnstert.2018.04.002.","DOI":"10.1016\/j.fertnstert.2018.04.002"},{"issue":"92","key":"2111_CR75","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.cryobiol.2019.12.001","volume":"1","author":"R Sciorio","year":"2020","unstructured":"Sciorio R, Anderson RA. Fertility preservation and preimplantation genetic assessment for women with breast cancer. Cryobiology. 2020;1(92):1\u20138. https:\/\/doi.org\/10.1016\/j.cryobiol.2019.12.001.","journal-title":"Cryobiology"},{"issue":"5","key":"2111_CR76","doi-asserted-by":"publisher","first-page":"726","DOI":"10.1089\/jayao.2023.0191","volume":"13","author":"H Kuntz","year":"2024","unstructured":"Kuntz H, Santucci J, Butts S, Dandekar S, Smink G, Van Scoy LJ, et al. Determinants of decision regret regarding fertility preservation in adolescent and young adult cancer survivors: a systematic review. J Adolesc Young Adult Oncol. 2024;13(5):726\u201337. https:\/\/doi.org\/10.1089\/jayao.2023.0191.","journal-title":"J Adolesc Young Adult Oncol"},{"key":"2111_CR77","doi-asserted-by":"publisher","DOI":"10.1007\/s11764-025-01809-1","author":"N Abdo","year":"2025","unstructured":"Abdo N, Thom B, Chang C, Feldman M, Benedict C, Semler R, et al. Decisions of young women with breast cancer regarding fertility preservation before cancer treatment and family building after treatment. J Cancer Surviv. 2025. https:\/\/doi.org\/10.1007\/s11764-025-01809-1.","journal-title":"J Cancer Surviv"},{"issue":"2","key":"2111_CR78","doi-asserted-by":"publisher","first-page":"116","DOI":"10.1002\/jso.24418","volume":"115","author":"JV Vu","year":"2017","unstructured":"Vu JV, Llarena NC, Estevez SL, Moravek MB, Jeruss JS. Oncofertility program implementation increases access to fertility preservation options and assisted reproductive procedures for breast cancer patients. J Surg Oncol. 2017;115(2):116\u201321. https:\/\/doi.org\/10.1002\/jso.24418.","journal-title":"J Surg Oncol"},{"issue":"8","key":"2111_CR79","doi-asserted-by":"publisher","first-page":"e764","DOI":"10.1016\/j.clbc.2024.09.003","volume":"24","author":"M Swain","year":"2024","unstructured":"Swain M, Miller M, Cannella C, Doe S, Petersen L, Bensenhaver J. A retrospective study of fertility counseling and preservation rates for women of reproductive age with breast care after integrating a fertility specialist into a multidisciplinary tumor board. Clin Breast Cancer. 2024;24(8):e764\u201371. https:\/\/doi.org\/10.1016\/j.clbc.2024.09.003.","journal-title":"Clin Breast Cancer"},{"key":"2111_CR80","doi-asserted-by":"publisher","DOI":"10.1007\/s11764-024-01720-1","author":"L Bentsen","year":"2024","unstructured":"Bentsen L, Colmorn LB, Pappot H, Macklon KT, Vassard D. Impact of cancer during reproductive age on the probability of livebirth after cancer: a register-based cohort study among Danish women aged 18\u201339 with and without cancer. J Cancer Surviv. 2024. https:\/\/doi.org\/10.1007\/s11764-024-01720-1.","journal-title":"J Cancer Surviv"},{"issue":"10","key":"2111_CR81","doi-asserted-by":"publisher","first-page":"1438","DOI":"10.1001\/jamaoncol.2022.3677","volume":"8","author":"A Marklund","year":"2022","unstructured":"Marklund A, Lekberg T, Hedayati E, Liljegren A, Bergh J, Lundberg FE, et al. Relapse rates and disease-specific mortality following procedures for fertility preservation at time of breast cancer diagnosis. JAMA Oncol. 2022;8(10):1438\u201346. https:\/\/doi.org\/10.1001\/jamaoncol.2022.3677.","journal-title":"JAMA Oncol"},{"issue":"3","key":"2111_CR82","doi-asserted-by":"publisher","first-page":"593","DOI":"10.1007\/s10549-021-06232-5","volume":"188","author":"C Leproux","year":"2021","unstructured":"Leproux C, Seegers V, Patsouris A, Sauterey B. Success and risks of pregnancy after breast cancer. Breast Cancer Res Treat. 2021;188(3):593\u2013600. https:\/\/doi.org\/10.1007\/s10549-021-06232-5.","journal-title":"Breast Cancer Res Treat"},{"issue":"1","key":"2111_CR83","doi-asserted-by":"publisher","first-page":"86","DOI":"10.1001\/jamaoncol.2020.5957","volume":"7","author":"A Marklund","year":"2021","unstructured":"Marklund A, Lundberg FE, Eloranta S, Hedayati E, Pettersson K, Rodriguez-Wallberg KA. Reproductive outcomes after breast cancer in women with vs without fertility preservation. JAMA Oncol. 2021;7(1):86\u201391. https:\/\/doi.org\/10.1001\/jamaoncol.2020.5957.","journal-title":"JAMA Oncol"},{"issue":"29","key":"2111_CR84","doi-asserted-by":"publisher","first-page":"3293","DOI":"10.1200\/JCO.21.00535","volume":"39","author":"M Lambertini","year":"2021","unstructured":"Lambertini M, Blondeaux E, Bruzzone M, Perachino M, Anderson RA, de Azambuja E, et al. Pregnancy after breast cancer: a systematic review and meta-analysis. J Clin Oncol. 2021;39(29):3293\u2013305. https:\/\/doi.org\/10.1200\/JCO.21.00535.","journal-title":"J Clin Oncol"},{"issue":"3","key":"2111_CR85","doi-asserted-by":"publisher","first-page":"818","DOI":"10.1016\/s0002-9378(94)70290-x","volume":"170","author":"R Sankila","year":"1994","unstructured":"Sankila R, Hein\u00e4vaara S, Hakulinen T. Survival of breast cancer patients after subsequent term pregnancy: \u201chealthy mother effect.\u201d Am J Obstet Gynecol. 1994;170(3):818\u201323. https:\/\/doi.org\/10.1016\/s0002-9378(94)70290-x.","journal-title":"Am J Obstet Gynecol"},{"issue":"15","key":"2111_CR86","doi-asserted-by":"publisher","first-page":"1086","DOI":"10.1056\/NEJM200010123431506","volume":"343","author":"HJ Burstein","year":"2000","unstructured":"Burstein HJ, Winer EP. Primary care for survivors of breast cancer. N Engl J Med. 2000;343(15):1086\u201394. https:\/\/doi.org\/10.1056\/NEJM200010123431506.","journal-title":"N Engl J Med"},{"key":"2111_CR87","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1016\/j.ejca.2017.03.035","volume":"79","author":"A Dezellus","year":"2017","unstructured":"Dezellus A, Barriere P, Campone M, Lemanski C, Vanlemmens L, Mignot L, et al. Prospective evaluation of serum anti-M\u00fcllerian hormone dynamics in 250 women of reproductive age treated with chemotherapy for breast cancer. Eur J Cancer. 2017;79:72\u201380. https:\/\/doi.org\/10.1016\/j.ejca.2017.03.035.","journal-title":"Eur J Cancer"},{"issue":"15","key":"2111_CR88","doi-asserted-by":"publisher","first-page":"1569109","DOI":"10.3389\/fonc.2025.1569109","volume":"26","author":"Q Song","year":"2025","unstructured":"Song Q, Mei H, Lu W, Zhang W, Liu J, Wang X, et al. Reproductive outcomes of pregnancy after breast cancer: an updated systematic review and meta-analysis. Front Oncol. 2025Sep;26(15):1569109. https:\/\/doi.org\/10.3389\/fonc.2025.1569109.","journal-title":"Front Oncol"},{"issue":"5","key":"2111_CR89","doi-asserted-by":"publisher","first-page":"1070","DOI":"10.3390\/cancers13051070","volume":"13","author":"J Labrosse","year":"2021","unstructured":"Labrosse J, Lecourt A, Hours A, Sebbag C, Toussaint A, Laas E, et al. Time to pregnancy, obstetrical and neonatal outcomes after breast cancer: a study from the maternity network for young breast cancer patients. Cancers (Basel). 2021;13(5):1070. https:\/\/doi.org\/10.3390\/cancers13051070.","journal-title":"Cancers (Basel)"},{"issue":"10","key":"2111_CR90","doi-asserted-by":"publisher","first-page":"3032","DOI":"10.1245\/s10434-019-07596-1","volume":"26","author":"HM Johnson","year":"2019","unstructured":"Johnson HM, Mitchell KB. Breastfeeding and breast cancer: managing lactation in survivors and women with a new diagnosis. Ann Surg Oncol. 2019;26(10):3032\u20139. https:\/\/doi.org\/10.1245\/s10434-019-07596-1.","journal-title":"Ann Surg Oncol"},{"key":"2111_CR91","doi-asserted-by":"publisher","unstructured":"Practice Committee of the American Society for Reproductive Medicine and Practice Committee of the Society for Assisted Reproductive Technology. Electronic address: asrm@asrm.org. Recommendations for practices using gestational carriers: a committee opinion. Fertil Steril. 2022;118(1):65\u201374. https:\/\/doi.org\/10.1016\/j.fertnstert.2022.05.001.\u00a0","DOI":"10.1016\/j.fertnstert.2022.05.001"},{"key":"2111_CR92","doi-asserted-by":"publisher","unstructured":"Tanaka Y, Amano T, Nakamura A, Takahashi A, Takebayashi A, Hanada T, Tsuji S, Murakami T. Balancing fertility preservation and treatment efficacy in (neo)adjuvant therapy for adolescent and young adult breast cancer patients: a narrative review. Curr Oncol Rep. 2024;26(12):1563\u201374. https:\/\/doi.org\/10.1007\/s11912-024-01615-5.","DOI":"10.1007\/s11912-024-01615-5"},{"issue":"10","key":"2111_CR93","doi-asserted-by":"publisher","first-page":"e415","DOI":"10.1016\/S1470-2045(23)00390-X","volume":"24","author":"W Cui","year":"2023","unstructured":"Cui W, Rocconi RP, Thota R, Anderson RA, Bruinooge SS, Comstock IA, et al. Measuring ovarian toxicity in clinical trials: an American Society of Clinical Oncology research statement. Lancet Oncol. 2023;24(10):e415\u201323. https:\/\/doi.org\/10.1016\/S1470-2045(23)00390-X.","journal-title":"Lancet Oncol"},{"issue":"12","key":"2111_CR94","doi-asserted-by":"publisher","first-page":"1770","DOI":"10.1093\/jnci\/djab111","volume":"113","author":"W Cui","year":"2021","unstructured":"Cui W, Francis PA, Loi S, Hickey M, Stern C, Na L, et al. Assessment of ovarian function in phase III (neo)adjuvant breast cancer clinical trials: a systematic evaluation. J Natl Cancer Inst. 2021;113(12):1770\u20138. https:\/\/doi.org\/10.1093\/jnci\/djab111.","journal-title":"J Natl Cancer Inst"},{"key":"2111_CR95","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1016\/j.breast.2022.05.002","volume":"64","author":"W Cui","year":"2022","unstructured":"Cui W, Phillips KA, Francis PA, Anderson RA, Partridge AH, Loi S, et al. Understanding the barriers to, and facilitators of, ovarian toxicity assessment in breast cancer clinical trials. Breast. 2022;64:56\u201362. https:\/\/doi.org\/10.1016\/j.breast.2022.05.002.","journal-title":"Breast"}],"container-title":["Journal of Cancer Survivorship"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11764-026-02111-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11764-026-02111-4","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11764-026-02111-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,29]],"date-time":"2026-08-29T14:39:59Z","timestamp":1788014399000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11764-026-02111-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,29]]},"references-count":95,"alternative-id":["2111"],"URL":"https:\/\/doi.org\/10.1007\/s11764-026-02111-4","relation":{},"ISSN":["1932-2259","1932-2267"],"issn-type":[{"value":"1932-2259","type":"print"},{"value":"1932-2267","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,29]]},"assertion":[{"value":"19 January 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 August 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 August 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}}]}}